BBR Partners LLC purchased a new position in Grail, Inc. (NASDAQ:GRAL - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 50,001 shares of the company's stock, valued at approximately $893,000. BBR Partners LLC owned about 0.15% of Grail at the end of the most recent quarter.
Several other institutional investors and hedge funds have also made changes to their positions in the stock. Douglas Lane & Associates LLC purchased a new position in shares of Grail in the fourth quarter worth about $3,034,000. A. D. Beadell Investment Counsel Inc. purchased a new position in Grail during the 4th quarter worth approximately $430,000. FNY Investment Advisers LLC purchased a new position in Grail during the 4th quarter worth approximately $26,000. 180 Wealth Advisors LLC acquired a new stake in Grail during the 4th quarter valued at approximately $1,681,000. Finally, B & T Capital Management DBA Alpha Capital Management purchased a new stake in shares of Grail in the 4th quarter valued at $387,000.
Grail Trading Down 4.8 %
NASDAQ:GRAL traded down $1.55 during trading hours on Tuesday, reaching $30.54. The company had a trading volume of 2,117,937 shares, compared to its average volume of 1,223,951. Grail, Inc. has a 1-year low of $12.33 and a 1-year high of $63.99. The business's 50 day moving average price is $30.91 and its 200-day moving average price is $20.98.
Grail (NASDAQ:GRAL - Get Free Report) last posted its earnings results on Thursday, February 20th. The company reported ($1.86) earnings per share (EPS) for the quarter, beating the consensus estimate of ($4.41) by $2.55. The firm had revenue of $38.25 million during the quarter, compared to analyst estimates of $35.33 million. As a group, analysts forecast that Grail, Inc. will post -15.15 EPS for the current year.
Analyst Ratings Changes
Several research analysts recently issued reports on the stock. Wolfe Research initiated coverage on shares of Grail in a report on Friday, November 15th. They set a "peer perform" rating for the company. Morgan Stanley started coverage on Grail in a research note on Wednesday, November 27th. They set an "equal weight" rating and a $16.00 price objective for the company.
Get Our Latest Analysis on Grail
Grail Profile
(
Free Report)
GRAIL, Inc is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.
Further Reading
Before you consider Grail, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Grail wasn't on the list.
While Grail currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
